Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mayinglong Pharmaceutical Group Co., Ltd. (600993.SS)
CNY24.38
+0.32 (+1.33%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
100 Zhoujia Wan 430064
Wuhan, CN
Wuhan, CN
CEO
Youzhang Xia
Website
mayinglong.cn
IPO
2004-05-17
ISIN CNE000001HN2
Description
Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY24.38
+0.32 (+1.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.32
Float Shares
275.79M
Free Float %
64.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.86% | +0.37% | -7.07% | -10.17% | -11.84% | -13.61% | -16.59% | -18.85% | +6.94% | +29.15% | +956.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
24.38
DCF (Unlevered)
41.63
+70.7%
DCF (Levered)
39.86
+63.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.63
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.7% Q1'26: +4.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+9.8% Q1'26: +4.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.3% Q1'26: +21.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.5% ★ Q1'26: +25.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+30.6% ★ Q1'26: +39.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.10× ★ Q1'26: 0.08× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.78B
est: 1.84B (-3.3%)
|
2.10B
est: 1.84B (+14.0%)
|
1.75B
est: 1.97B (-11.4%)
|
2.20B
est: 1.63B (+35.0%)
|
2.71B
est: 2.40B (+12.9%)
|
2.79B
est: 2.82B (-0.8%)
|
3.39B
est: 3.24B (+4.5%)
|
3.53B
est: 3.67B (-3.6%)
|
3.14B
est: 4.92B (-36.3%)
|
3.73B
est: 3.70B (+0.8%)
|
3.87B
est: 4.06B (-4.7%)
|
4.23B
4.23B – 4.23B
+4.4% YoY
|
4.64B
4.64B – 4.64B
+9.6% YoY
|
5.07B
5.04B – 5.11B
+9.3% YoY
|
| EBITDA |
280.33M
est: 273.81M (+2.4%)
|
321.72M
est: 273.81M (+17.5%)
|
404.28M
est: 293.25M (+37.9%)
|
233.01M
est: 241.74M (-3.6%)
|
464.51M
est: 355.80M (+30.6%)
|
540.65M
est: 418.06M (+29.3%)
|
600.67M
est: 481.09M (+24.9%)
|
622.47M
est: 544.23M (+14.4%)
|
590.84M
est: 730.92M (-19.2%)
|
708.55M
est: 696.91M (+1.7%)
|
810.78M
est: 763.97M (+6.1%)
|
797.35M
797.35M – 797.35M
+4.4% YoY
|
874.30M
874.30M – 874.30M
+9.6% YoY
|
955.38M
948.81M – 961.95M
+9.3% YoY
|
| EBIT |
256.25M
est: 249.56M (+2.7%)
|
285.23M
est: 249.56M (+14.3%)
|
368.22M
est: 267.28M (+37.8%)
|
196.66M
est: 220.34M (-10.7%)
|
428.36M
est: 324.30M (+32.1%)
|
505.40M
est: 381.04M (+32.6%)
|
558.93M
est: 438.50M (+27.5%)
|
575.49M
est: 496.04M (+16.0%)
|
541.36M
est: 666.20M (-18.7%)
|
664.93M
est: 639.55M (+4.0%)
|
716.38M
est: 701.08M (+2.2%)
|
731.72M
731.72M – 731.72M
+4.4% YoY
|
802.33M
802.33M – 802.33M
+9.6% YoY
|
876.74M
870.72M – 882.77M
+9.3% YoY
|
| Net Income |
223.26M
est: 237.08M (-5.8%)
|
250.24M
est: 237.08M (+5.6%)
|
320.05M
est: 250.67M (+27.7%)
|
176.21M
est: 278.12M (-36.6%)
|
359.97M
est: 326.12M (+10.4%)
|
419.06M
est: 320.46M (+30.8%)
|
464.59M
est: 362.14M (+28.3%)
|
478.57M
est: 481.66M (-0.6%)
|
443.25M
|
528.09M
est: 561.39M (-5.9%)
|
581.49M
est: 607.34M (-4.3%)
|
681.64M
681.64M – 681.64M
+12.2% YoY
|
745.00M
705.54M – 827.88M
+9.3% YoY
|
862.55M
862.55M – 862.55M
+15.8% YoY
|
| SGA |
460.37M
est: 466.54M (-1.3%)
|
495.41M
est: 466.54M (+6.2%)
|
534.03M
est: 499.67M (+6.9%)
|
606.72M
est: 411.90M (+47.3%)
|
643.68M
est: 606.25M (+6.2%)
|
654.35M
est: 712.33M (-8.1%)
|
810.85M
est: 819.73M (-1.1%)
|
880.65M
est: 927.31M (-5.0%)
|
819.59M
est: 1.25B (-34.2%)
|
1.05B
est: 924.32M (+13.1%)
|
844.71M
est: 1.01B (-16.6%)
|
1.06B
1.06B – 1.06B
+4.4% YoY
|
1.16B
1.16B – 1.16B
+9.6% YoY
|
1.27B
1.26B – 1.28B
+9.3% YoY
|
| EPS |
0.52
est: 0.55 (-5.5%)
|
0.58
est: 0.55 (+5.5%)
|
0.74
est: 0.58 (+27.3%)
|
0.41
est: 0.65 (-36.5%)
|
0.84
est: 0.76 (+11.0%)
|
0.97
est: 0.74 (+30.5%)
|
1.08
est: 0.84 (+28.6%)
|
1.11
est: 1.12 (-0.7%)
|
1.03
|
1.23
est: 1.30 (-5.6%)
|
1.35
est: 1.41 (-4.3%)
|
1.58
1.58 – 1.58
+12.2% YoY
|
1.78
1.64 – 1.92
+12.5% YoY
|
2.00
2.00 – 2.00
+12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
575.34M
OE per share TTM
1.33
Owner's Yield
5.48%
Maintenance CapEx ratio
4.71%
Maint CapEx / Avg PPE
16.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 385.3K | 0.06% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 211.3K | 0.39% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 9.6K | 0.44% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 107.4K | 0.28% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 27.3K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 12.1K | 0.48% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 81.1K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.35M | 0.06% |
| 9 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 8.5K | 0.46% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 19.3K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
248.6K
Shares Outstanding
431.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daonian Zhou | Deputy General Manager | — | male |
| Peng Ling | Head of Accounting Agency | — | — |
| Ping An Liu | Deputy GM & Director | — | male |
| Qian Ma | Deputy GM & Secretary to the Board of Directors | — | female |
| Tao Mao | Financial Director & Chief Financial Officer | — | male |
| Wei Zhang | Deputy General Manager | — | male |
| Youzhang Xia | GM & Director | — | male |
| Zheng Jun Tian | Deputy General Manager | — | male |
| Zhi Qi Song | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600993.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
